Among them, the ENPP1 inhibitor RBS2418, developed by Riboscience, has entered Phase I clinical trials.[19] The clinical results in 11 different cancer types show that oral RBS2418 treatment has significant clinical benefits, which supports further clinical development of this novel immunotherapy agent.[20] So far, ENPP1 is the only detectable protease that can hydrolyze immune transmitter 2′3′‐cGAMP. Here, ENPP1 is linked to cancer.